AFMD: Affimed NV Price to Sales
Affimed (AFMD) revenue valuation reflects a trend with the metric currently at 3.10. Current cash reserves at Affimed allow for the systematic funding of immuno-oncology developments. Capital expenditure efficiency is achieved by outsourcing late-stage production to external contractors. Meanwhile, the leadership's scientific expertise in innate immune activation facilitates the formation of strategic alliances with pharma behemoths.
Analytical breakdowns for Affimed (AFMD)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- debt obligations and liquidity statistics:
- company profitability and valuation multiples indicators:
AFMD - Net Profit|Projected Future Earnings Affimed|AFMD - P/E Multiple|Price to Expected Earnings Ratio affimed.com|AFMD - Price/Earnings to Growth Ratio|Enterprise Value to EBITDA Ratio Affimed Therapeutics|AFMD - Operating profit EBITDA|Earnings per share for the last 12 months Affimed|AFMD - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months affimed.com|AFMD - Earnings growth in current year|Expected earnings per share trend next year Affimed
- issuer revenue and sales details:
Fundamental company analysis:AFMD (Affimed NV)
Affimed monetizes its biotechnological developments through long-term licensing agreements with pharmaceutical corporations. An analysis of the price-to-sales ratio allows for a comparison of market capitalization against the volume of these inflows, determining how much investors are willing to pay per unit of the company's revenue, which serves as a key indicator of the asset's fundamental overvaluation or undervaluation over the long term.
Competing companies
argenx.com - Market Cap to Revenue Ratio|P/S Multiple BNTX (BioNTech)|Abivax Pharma (ABVX) - Price to Sales|ADMA Bio - P/S Multiple|PTGX - P/S Multiple|IMVT: P/S Multiple|Price-to-Sales Ratio KNSA (kiniksa.com)|GRFS (Grifols) - P/S Multiple|Adaptive Biotech - Price-to-Sales Ratio|P/S Multiple CLDX|Price-to-Revenue Coefficient Aurinia Corp|Price-to-Revenue Ratio BioCryst BCRX|VERA - Market Cap to Revenue|Dianthus Therapeutics, Inc. - P/S Multiple|Price to Sales Pharvaris NV|ABCL: P/S Multiple|Market Cap to Revenue Ratio TRML|PGEN (Precigen, Inc.) - P/S Multiple|P/S Multiple pharming.com|P/S Multiple NKTR|UPB: Price-to-Sales Ratio|Price-to-Revenue Ratio Zenas Biopharma, Inc. ZBIO|IMNM - Market Cap to Revenue|Gossamer Bio, Inc. - P/S Multiple|KALV (kalvista.com) - Market Cap to Revenue Ratio|Septerna (SEPN) - Price-to-Revenue Ratio|Price-to-Sales Ratio PVLA (Pieris Pharma)|SVRA (Savara Corp) - P/S Multiple|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|Price-to-Revenue Ratio enGene ENGN|Market Capitalization-to-Revenue Ratio RAPT|JBIO - Price-to-Revenue Ratio|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Market Cap to Revenue CABA|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|Price-to-Revenue Coefficient Avalo Therapeutics Inc|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|AGEN - Market Cap to Revenue|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR (aTyr) - Market Cap to Revenue|Adagene Inc. (ADAG) - P/S Multiple|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Ratio STTK (Shattuck Therapeutics)|P/S Multiple EQ|CNTB - Price to Sales|P/S Multiple IMUX (Immunic)|P/S Multiple Atara Biotherapeutics, Inc. ATRA|InflaRx GmbH - P/S Multiple|Price-to-Sales Ratio XFOR|ACET: P/S Multiple|Price-to-Sales Ratio CELU (Celularity)|INMB (INmune Bio Corp) - P/S Multiple|Barinthus Biotherapeutics Corp (BRNS) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|Market Cap to Revenue sabbiotherapeutics.com SABS|P/S Multiple AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Price to Sales|Q32 Bio Corp - P/S Multiple|GOVX (GeoVax Corp) - Market Cap to Revenue Ratio|EDSA: P/S Multiple|ibioinc.com (IBIO) - P/S Multiple|CARM (Carisma Therapeutics Inc) - P/S Multiple|XTL Biopharmaceuticals Ltd - Price-to-Sales Ratio|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|Market Cap to Revenue hcwbiologics.com HCWB|P/S Multiple APVO (Aptevo Therapeutics Inc.)|AIM: Market Cap to Revenue Ratio|ADTX - Price-to-Revenue Ratio|Price-to-Sales Ratio GRI|XRTX: P/S Multiple|Vyome Therapeutics - Market Capitalization-to-Revenue Ratio|REVB (Revelation Biosciences) - P/S Multiple|P/S Multiple indaptusrx.com|Price-to-Revenue Ratio Scinai Immunotherapeutics Ltd. (SCNI)|CALI (calcimedica.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Allakos ALLK|HOOK - Market Cap to Revenue|IGM Bio - P/S Multiple|ITOS - P/S Multiple|OCEA (Ocean Biomedical) - Market Cap to Revenue|TC BioPharm (Holdings) Plc - Market Capitalization-to-Revenue Ratio|THRD (Third Harmonic Bio, Inc) - P/S Multiple
